Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes

Diabetes

Volumn 51, Issue 3, 2002, Pages 808-812

  Scognamiglio, Roldano ^a,b   Avogaro, Angelo ^a   De Kreutzenberg, Saula Vigili ^a   Negut, Christian ^a   Palisi, Monica ^a   Bagolin, Eros ^a   Tiengo, Antonio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRIDAMOLE; GLIBENCLAMIDE; INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MOVEMENT; HEART MUSCLE ISCHEMIA; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 0036314661     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.3.808     Document Type: Article

References (40)

1. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
2. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects
3. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction: Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II
4. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents
5. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty
6. Coronary angioplasty in diabetic patients
7. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium
8. ATP-sensitive potassium channels and myocardial preconditioning
9. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: Clinical, hemodynamic, and metabolic features
10. Does ischemic preconditioning occur in patients?
11. Improvement in ischemic parameters during repeated exercise testing: A possible model for myocardial preconditioning
12. ATP blockade in type II diabetes and preconditioning in cardiovascular disease: Time for reconsideration
13. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: Two paradoxes revisited
14. The sulfonylurea receptor
15. + channel-opening drugs
16. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography
17. Cross-sectional echocardiography. II. Analysis of mathematic models for quantifying volume of the formalin-fixed left ventricle
18. Myocardial metabolism in insulindeficient diabetic humans without coronary artery disease
19. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM
20. Echocardiographic load-independent indices of contractility in children and adolescents with type I diabetes: Effect of metabolic control and insulin on left ventricular performance
21. Energy metabolism after ischemic preconditioning in streptozotocin-induced diabetic rat hearts
22. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
23. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction
24. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type I receptor blockade on cardiac remodeling after myocardial infarction in the rat
25. Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation
26. ATP channels
27. Oral hypoglycemic agents
28. ATP channel in preconditioning
29. Effect of plasma insulin level on myocardial blood flow and its mechanism of action
30. Insulin improves functional and metabolic recovery of reperfused working rat heart
31. State of the art for coronary artery disease detection: Thallium-201
32. Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men
33. Early impairment of coronary flow reserve in young men with borderline hypertension
34. Coronary flow reserve in young men with familial combined hyperlipidemia
35. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine
36. Assessment of the effects of dobutamine on myocardial blood flow and oxidative metabolism in non nal human subjects using nitrogen-13 ammonia and carbon-11 acetate
37. Dobutamine positron emission tomography: Absolute quantitation of rest and dobutamine myocardial blood flow and correlation with cardiac work and percent diameter stenosis in patients with and without coronary artery disease
38. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus
39. Dobutamine stress: Effects on regional myocardial blood flow and wall motion
40. Pathophysiological mechanism of defective inotropic response to a β-adrenergic agonist in the diabetic heart